Pfizer vs Moderna

Pfizer vs Moderna: What investors need to know

Pfizer and Moderna share the unusual distinction of having generated over $100 billion each in COVID vaccine revenue — and both now face the challenge of building sustainable businesses after that pandemic windfall. Pfizer is a large, diversified pharmaceutical company with revenue across oncology, cardiology, rare diseases, and vaccines. It used its COVID profits to fund major acquisitions (including Seagen for oncology). Moderna is almost entirely dependent on mRNA vaccine technology and has limited revenue diversification beyond COVID boosters. Pfizer carries lower risk — it has multiple revenue streams, a deep pipeline, and decades of commercial infrastructure. Moderna is effectively a high-risk biotech bet on mRNA technology reaching beyond vaccines into cancer and rare disease treatment.

Common questions